New pill aims to tame bipolar mania without lifelong side effects?
NCT ID NCT07288320
First seen Jan 08, 2026 · Last updated May 17, 2026 · Updated 24 times
Summary
This study tests an experimental drug, NBI-1117568, to see if it can reduce manic symptoms in adults with bipolar I disorder who are hospitalized for a manic episode. About 150 participants will receive either the drug or a placebo for 21 days. The main goal is to measure changes in mania severity using a standard rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, California, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGSan Diego, California, 92123, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30331, United States
-
Neurocrine Clinical Site
RECRUITINGGaithersburg, Maryland, 20877, United States
-
Neurocrine Clinical Site
RECRUITINGMarlton, New Jersey, 08053, United States
Conditions
Explore the condition pages connected to this study.